

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
11 May 2023 (11.05.2023)



(10) International Publication Number
WO 2023/081370 A1

(51) International Patent Classification:

A61P 1/16 (2006.01) G01N 33/487 (2006.01)
G01N 33/92 (2006.01)

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(21) International Application Number:

PCT/US2022/048978

(22) International Filing Date:

04 November 2022 (04.11.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/276,480 05 November 2021 (05.11.2021) US
63/315,762 02 March 2022 (02.03.2022) US

(71) Applicant: MIRUM PHARMACEUTICALS, INC.

[US/US]; 950 Tower Lane, Suite 1050, Foster City, CA 94404 (US).

(72) Inventors: VIG, Pamela; c/o Mirum Pharmaceuticals, Inc.,

950 Tower Lane, Suite 1050, Foster City, CA 94404 (US).

GARNER, Will; c/o Mirum Pharmaceuticals, Inc., 950

Tower Lane, Suite 1050, Foster City, CA 94404 (US).

(74) Agent: KHANKIN, Alina K. et al.; Troutman Pepper

Hamilton Sanders LLP, 875 Third Avenue, 17th Floor, New York, NY 10022 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: TREATMENT WITH ILEAL BILE ACID TRANSPORTER (IBAT) INHIBITORS FOR INCREASED EVENT-FREE SURVIVAL (EFS)

(57) Abstract: The present invention relates generally to methods treating cholestatic liver disease by administering an ileal bile acid transporter inhibitor (IBAT inhibitor), wherein the treatment results in increased event-free survival (EFS). The present invention relates also to methods for providing a prediction of response to an IBAT inhibitor therapy for treatment of cholestatic liver disease by predicting EFS.

WO 2023/081370 A1